同时有三分之一的肿瘤缩小了至少80%。在最后一次的检查中,这种治疗对90%的病人继续有效。
This, then, is good news for those with melanoma.
这对于患有黑色素瘤的病人是个莫大的好消息。
But the most intriguing paper of the series was delivered by Roy Herbst, who also works atYale.
然而这些论文中最令人激动的要数同在耶鲁工作的Roy Herbst所发表的论文。
He and his colleagues are testing MPDL3280A in a trial open to people who have any type ofmetastatic or otherwise incurable tumourthose, in other words, for whom establishedtreatments offer no hope.
他和同事们在一轮实验中测试MPDL3280A,并且面向所有患有任何转移性或者不可治愈肿瘤的人,换句话说,这些病人的肿瘤是目前成熟的治疗手段所不能治疗的。
Preliminary results suggest a fifth of the 140 patients in this trial are responding. And, as inthe case of Dr Wolchok s work, these responses are long-lasting.
该实验的初步结果显示140名病人中有五分之一产生反应,并且这些反应长期持续,恰如Wolchok博士研究中观察到的那样。
The crucial point in the MPDL3280A trial is that those who have responded have a range ofcancersnot just melanoma.
【2015考研英语阅读癌症治疗】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30